Both Baricitinib And Ravulizumab Ineffective As Adjuncts To Standard Care In Patients With Severe COVID-19 Infection, Study Finds

Infectious Disease Advisor (12/27, Kuhns) reports, “Both baricitinib and ravulizumab are ineffective as adjuncts to standard care in patients with severe COVID-19 infection,” according to recent study results. The findings were published in The Lancet Respiratory Medicine.